Inhibitors of Coronavirus Fidelity and Cap Methylation as Broadly Applicable

冠状病毒保真度和帽甲基化抑制剂广泛适用

基本信息

批准号：
9217551
负责人：
Mark R Denison
金额：
$ 101.98万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-01 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9217551
关键词：
5&apos -exoribonuclease Ablation Acute Animals Antiviral Agents Area Attenuated Binding Biological Biological Assay Biological Availability Chemicals Chiroptera Coronaviridae Coronavirus Coronavirus Infections Data Set Development Disease Drug Targeting Enzymes Europe Exons Family Family member Frequencies Genes Genetic Genome Goals Histology Human Immune Impairment In Vitro Innate Immune Response Interferons Lead Lower Respiratory Tract Infection Mediating Methylation Methyltransferase Middle East Modeling Monitor Morbidity - disease rate Movement Mus Mutagenesis Mutagens Mutation Nonstructural Protein Pathogenesis Pathway interactions Pharmaceutical Chemistry Phenotype Process RNA RNA Caps RNA-Directed RNA Polymerase Resistance development Respiratory physiology Ribonucleosides SARS coronavirus Severity of illness Solubility Technology Testing Therapeutic Treatment Efficacy Viral Viral Proteins Virulence Virulent Virus Virus Replication Work analog attenuation drug development drug discovery efficacy testing experience fitness high throughput screening human disease in vivo inhibitor/antagonist mortality mouse model novel programs protein function public health priorities replicase reverse genetics screening small molecule inhibitor small molecule libraries therapeutic target transmission process viral RNA viral detection viral fitness viral resistance virus development

项目摘要

Both the emergence and subsequent human-to-human transmission of SARS-CoV in 2002-2003, and ofthe highly virulent human coronavirus HCoV-EMC in the Middle East and Europe in 2012-2013 exemplifies CoV movement potential and transmissibility, and underscores the urgent and critical need for a broadly efficacious therapeutics. The overall goal of Project 2 is to identify inhibitors of two highly conserved CoV processes, replication fidelity and RNA capping, that are essential for SARS-CoV virulence and survival in vivo. Multiple viral proteins and enzymatic activities are critical for these processes, including CoV 3'-to-5' exoribonuclease (fidelity; nsp14-ExoN) and 2'-0-methyltransferase (capping; nsp16-0MTase) activities. Consistent with the importance of these processes, we have shown that decreased replication fidelity and ablation of RNA capping through genetic inactivation of either ExoN or OMTase, respectively, results in replication competent viruses that are profoundly attenuated in vivo. In Aims 1 and 2, we will work with the Screening Core (Core B) and the Medicinal Chemistry lead Development Core (Core C) to identify, characterize, and optimize small molecule inhibitors of SARS-CoV fidelity and RNA capping. Once active compounds are identified, we will define their mechanism of action, test for the development of virus resistance, and determine their activity across the CoV family. In Aim S, we will work with Core C to chemically optimize and test the in vivo efficacy of lead compounds in progressively tiered models of SARSCoV disease severity, and assess the development of drug resistance in vivo. The complementary expertise ofthe Denison and Baric Labs, extensive preliminary datasets, state-of-the-art technologies, and the expertise of SR in the areas of medicinal chemistry, high-throughput screening, and drug development will contribute significantly to the successful identification, confirmation, and in vivo testing of lead compounds. Ultimately, inhibiting these two conserved and distinct pathways required for in vivo pathogenesis will allow for the treatment of endemic and emerging CoVs and potentially reduce the emergence of viral resistance.

2002 - 2003年的SARS-COV的出现和随后的人类对人类对人类的传播，以及在2012 - 2013年在中东和欧洲在中东和欧洲高度毒气的人冠状病毒HCOV-EMC的出现，典型的典型和可传播性，并强调了迫切的，强调了广泛的效率治疗方法。项目2的总体目标是确定两个高度保守的COV过程的抑制剂，即复制保真度和RNA封盖，这对于SARS-COV毒力和体内生存至关重要。多种病毒蛋白和酶促活性对于这些过程至关重要，包括COV 3'-to-5'Exoriboneclease（Fidelity; NSP14-EXON）和2'-0-0-甲基转移酶（封盖； NSP16-0mtase）活性。与这些过程的重要性一致，我们已经表明，通过对外显子或OMTase的遗传失活的复制忠诚度和RNA限制的消融，导致复制有能力的病毒在体内严重减弱。在目标1和2中，我们将使用筛选核心（核心B）和药物化学铅发育核心（Core C），以识别，表征和优化SARS-COV Fidelity和RNA封盖的小分子抑制剂。一旦确定了活性化合物，我们将定义它们的作用机理，测试病毒抗性的发展，并确定它们在COV家族中的活性。在AIM中，我们将与Core C一起化学优化和测试SARSCOV疾病严重程度逐步分层模型中铅化合物的体内功效，并评估体内耐药性的发展。 Denison和Baric Labs的互补专业知识，广泛的初步数据集，最先进的技术以及SR在药用化学，高通量筛查和药物开发领域的SR专业知识将对成功的识别，确认，确认以及铅化合物的体内测试中的成功贡献。最终，抑制体内发病机理所需的这两种保守和不同的途径将允许治疗流行和新兴的COV，并有可能降低病毒抗性的出现。